Leerink analyst Marc Goodman downgraded Intra-Cellular (ITCI) to Market Perform from Outperform with a price target of $132, up from $100, after Johnson & Johnson (JNJ) agreed to acquire all of the company’s outstanding shares for $132 per share in cash. The firm doesn’t believe it’s likely that another player will come in at a higher price and doesn’t expect FTC pushback on the deal, the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ITCI:
- BofA moves to No Rating on Intra-Cellular after Johnson & Johnson deal
- Intra-Cellular downgraded to Neutral from Outperform at Baird
- J&J to acquire Intra-Cellular, Clearwater to buy Enfusion: Morning Buzz
- Biotech Alert: Searches spiking for these stocks today
- Intra-Cellular downgraded to Neutral from Overweight at Cantor Fitzgerald